Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
CELEGENCE LLC, headquartered in the United States, is a leading provider in the life sciences and healthcare industry, specialising in innovative solutions for clinical trials and regulatory compliance. Founded in 2015, CELEGENCE has rapidly established itself as a trusted partner for pharmaceutical and biotechnology companies, offering a suite of services that includes data management, clinical trial support, and regulatory consulting.
With a commitment to enhancing operational efficiency and ensuring compliance, CELEGENCE's unique approach combines advanced technology with deep industry expertise. The company has achieved significant milestones, including successful collaborations with major industry players and recognition for its contributions to improving clinical outcomes. CELEGENCE continues to solidify its market position through a focus on quality, innovation, and client satisfaction, making it a prominent name in the life sciences sector.
-9 vs industry average
CELEGENCE LLC’s score of 27 is lower than 49% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Business Services is among the least carbon-intensive industries
The Business Services industry has reduced its overall emissions by 25% since 2018
No reported emissions data is available for CELEGENCE LLC yet.
Celegence LLC, headquartered in the United States, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas emissions. Although specific emissions data for the most recent year is not available, the company has established a target to reduce its Scope 1 and Scope 2 emissions by 42% by 2030, using 2023 as the base year. This target has been validated through the Science Based Targets initiative (SBTi), which aligns with the necessary reductions to limit global warming to 1.5°C.
Celegence LLC's commitment also includes measuring and reducing its Scope 3 emissions, which encompass indirect emissions from its value chain. The company is classified as a small to medium-sized enterprise (SME) and is actively working towards these goals to enhance its sustainability profile within the pharmaceuticals, biotechnology, and life sciences sector.
These initiatives reflect Celegence LLC's dedication to addressing climate change and contributing to a more sustainable future, despite the absence of specific emissions totals at this time.
2030
42% reduction in Scope 1
Celegence LLC commits to reduce scope 1 and scope 2 GHG emissions 42% by 2030 from a 2023 base year, and to measure and reduce its scope 3 e…
2030
42% reduction in Scope 2
Celegence LLC commits to reduce scope 1 and scope 2 GHG emissions 42% by 2030 from a 2023 base year, and to measure and reduce its scope 3 e…
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more